SMO mutations may sometimes prevent long-term therapeutic benefits from occurring; in other circumstances, mutations in downstream components of the SHH pathway (for instance, MYCN or GLI2 amplifications) or in other pathways might render tumor cells resistant to these medications. Here, MYCN is linked to neoplasm.